A citation-based method for searching scientific literature

Kathleen Hawker, Paul O'Connor, Mark S Freedman, Peter A Calabresi, Jack Antel, Jack Simon, Stephen Hauser, Emmanuelle Waubant, Timothy Vollmer, Hillel Panitch, Jiameng Zhang, Peter Chin, Craig H Smith. Ann Neurol 2009
Times Cited: 608







List of co-cited articles
1105 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer,[...]. N Engl J Med 2017
916
78

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Stephen L Hauser, Emmanuelle Waubant, Douglas L Arnold, Timothy Vollmer, Jack Antel, Robert J Fox, Amit Bar-Or, Michael Panzara, Neena Sarkar, Sunil Agarwal,[...]. N Engl J Med 2008
58

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj,[...]. N Engl J Med 2017
885
54

Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Jeffrey A Cohen, Giancarlo Comi, Jorge Correale, Patricia K Coyle, Anne H Cross, Jerome de Seze, David Leppert, Xavier Montalban,[...]. N Engl J Med 2020
183
37

Defining the clinical course of multiple sclerosis: the 2013 revisions.
Fred D Lublin, Stephen C Reingold, Jeffrey A Cohen, Gary R Cutter, Per Soelberg Sørensen, Alan J Thompson, Jerry S Wolinsky, Laura J Balcer, Brenda Banwell, Frederik Barkhof,[...]. Neurology 2014
30

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Jonatan Salzer, Rasmus Svenningsson, Peter Alping, Lenka Novakova, Anna Björck, Katharina Fink, Protik Islam-Jakobsson, Clas Malmeström, Markus Axelsson, Mattias Vågberg,[...]. Neurology 2016
204
28

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Ludwig Kappos, Amit Bar-Or, Bruce A C Cree, Robert J Fox, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Douglas L Arnold, Sophie Arnould, Tatiana Scherz,[...]. Lancet 2018
457
26

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Amit Bar-Or, Peter A J Calabresi, Douglas Arnold, Clyde Markowitz, Stuart Shafer, Lloyd H Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J Fox, Michael Panzara,[...]. Ann Neurol 2008
383
23

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Chris H Polman, Paul W O'Connor, Eva Havrdova, Michael Hutchinson, Ludwig Kappos, David H Miller, J Theodore Phillips, Fred D Lublin, Gavin Giovannoni, Andrzej Wajgt,[...]. N Engl J Med 2006
20

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Ludwig Kappos, David Li, Peter A Calabresi, Paul O'Connor, Amit Bar-Or, Frederik Barkhof, Ming Yin, David Leppert, Robert Glanzman, Jeroen Tinbergen,[...]. Lancet 2011
485
20

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Fred Lublin, David H Miller, Mark S Freedman, Bruce A C Cree, Jerry S Wolinsky, Howard Weiner, Catherine Lubetzki, Hans-Peter Hartung, Xavier Montalban, Bernard M J Uitdehaag,[...]. Lancet 2016
279
20

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Alan J Thompson, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee, Giancarlo Comi, Jorge Correale, Franz Fazekas, Massimo Filippi, Mark S Freedman,[...]. Lancet Neurol 2018
19

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Christian Klein, Alfred Lammens, Wolfgang Schäfer, Guy Georges, Manfred Schwaiger, Ekkehard Mössner, Karl-Peter Hopfner, Pablo Umaña, Gerhard Niederfellner. MAbs 2013
200
19

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
Roberta Magliozzi, Owain Howell, Abhilash Vora, Barbara Serafini, Richard Nicholas, Maria Puopolo, Richard Reynolds, Francesca Aloisi. Brain 2007
919
19

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Mathias Granqvist, Malin Boremalm, Amyar Poorghobad, Anders Svenningsson, Jonatan Salzer, Thomas Frisell, Fredrik Piehl. JAMA Neurol 2018
117
18

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Amit Bar-Or, Richard A Grove, Daren J Austin, Jerry M Tolson, Susan A VanMeter, Eric W Lewis, Frederick J Derosier, Monica C Lopez, Sarah T Kavanagh, Aaron E Miller,[...]. Neurology 2018
102
18

Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.
Rui Li, Ayman Rezk, Yusei Miyazaki, Ellen Hilgenberg, Hanane Touil, Ping Shen, Craig S Moore, Laure Michel, Faisal Althekair, Sathy Rajasekharan,[...]. Sci Transl Med 2015
254
18

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Jeffrey A Cohen, Alasdair J Coles, Douglas L Arnold, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner, Elizabeth Fisher,[...]. Lancet 2012
802
17

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Edward Fox, Amy E Lovett-Racke, Matthew Gormley, Yue Liu, Maria Petracca, Sirio Cocozza, Richard Shubin, Sibyl Wray, Michael S Weiss, Jenna A Bosco,[...]. Mult Scler 2021
48
35

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman,[...]. Lancet Neurol 2018
173
17

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.
Owain W Howell, Cheryl A Reeves, Richard Nicholas, Daniele Carassiti, Bishan Radotra, Steve M Gentleman, Barbara Serafini, Francesca Aloisi, Federico Roncaroli, Roberta Magliozzi,[...]. Brain 2011
517
16

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Gustavo Luna, Peter Alping, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson,[...]. JAMA Neurol 2020
250
15

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Jerry S Wolinsky, Ponnada A Narayana, Paul O'Connor, Patricia K Coyle, Corey Ford, Kenneth Johnson, Aaron Miller, Lillian Pardo, Shaul Kadosh, David Ladkani. Ann Neurol 2007
289
15

Pathological mechanisms in progressive multiple sclerosis.
Don H Mahad, Bruce D Trapp, Hans Lassmann. Lancet Neurol 2015
664
15

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Richard A Rudick, William H Stuart, Peter A Calabresi, Christian Confavreux, Steven L Galetta, Ernst-Wilhelm Radue, Fred D Lublin, Bianca Weinstock-Guttman, Daniel R Wynn, Frances Lynn,[...]. N Engl J Med 2006
962
15

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.
Jeffrey M Gelfand, Bruce A C Cree, Stephen L Hauser. Neurotherapeutics 2017
90
16

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.
Ivan Jelcic, Faiez Al Nimer, Jian Wang, Verena Lentsch, Raquel Planas, Ilijas Jelcic, Aleksandar Madjovski, Sabrina Ruhrmann, Wolfgang Faigle, Katrin Frauenknecht,[...]. Cell 2018
232
15

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
Amit Bar-Or, Lama Fawaz, Boli Fan, Peter J Darlington, Aja Rieger, Christine Ghorayeb, Peter A Calabresi, Emmanuelle Waubant, Stephen L Hauser, Jiameng Zhang,[...]. Ann Neurol 2010
336
15

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.
Per S Sorensen, Steen Lisby, Richard Grove, Frederick Derosier, Steve Shackelford, Eva Havrdova, Jelena Drulovic, Massimo Filippi. Neurology 2014
191
14

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
Mika Komori, Yen Chih Lin, Irene Cortese, Andrew Blake, Joan Ohayon, Jamie Cherup, Dragan Maric, Peter Kosa, Tianxia Wu, Bibiana Bielekova. Ann Clin Transl Neurol 2016
95
14

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Xavier Montalban, Douglas L Arnold, Martin S Weber, Ivan Staikov, Karolina Piasecka-Stryczynska, Jonathan Willmer, Emily C Martin, Fernando Dangond, Sana Syed, Jerry S Wolinsky. N Engl J Med 2019
145
14

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.
Anne H Cross, Jennifer L Stark, Joanne Lauber, Michael J Ramsbottom, Jeri-Anne Lyons. J Neuroimmunol 2006
323
14

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.
Barbara Serafini, Barbara Rosicarelli, Roberta Magliozzi, Egidio Stigliano, Francesca Aloisi. Brain Pathol 2004
816
14

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Jerry S Wolinsky, Douglas L Arnold, Bruno Brochet, Hans-Peter Hartung, Xavier Montalban, Robert T Naismith, Marianna Manfrini, James Overell, Harold Koendgen, Annette Sauter,[...]. Lancet Neurol 2020
55
25

Multiple sclerosis.
Alan J Thompson, Sergio E Baranzini, Jeroen Geurts, Bernhard Hemmer, Olga Ciccarelli. Lancet 2018
831
13

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Peter Alping, Thomas Frisell, Lenka Novakova, Protik Islam-Jakobsson, Jonatan Salzer, Anna Björck, Markus Axelsson, Clas Malmeström, Katharina Fink, Jan Lycke,[...]. Ann Neurol 2016
151
13

Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.
Arumugam Palanichamy, Sarah Jahn, Dorothee Nickles, Mia Derstine, Aya Abounasr, Stephen L Hauser, Sergio E Baranzini, David Leppert, H-Christian von Büdingen. J Immunol 2014
166
13

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Alasdair J Coles, Cary L Twyman, Douglas L Arnold, Jeffrey A Cohen, Christian Confavreux, Edward J Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof W Selmaj, Howard L Weiner,[...]. Lancet 2012
793
13

The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells.
Joana Machado-Santos, Etsuji Saji, Anna R Tröscher, Manuela Paunovic, Roland Liblau, Galina Gabriely, Christian G Bien, Jan Bauer, Hans Lassmann. Brain 2018
240
13


A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Ludwig Kappos, Ernst-Wilhelm Radue, Paul O'Connor, Chris Polman, Reinhard Hohlfeld, Peter Calabresi, Krzysztof Selmaj, Catherine Agoropoulou, Malgorzata Leyk, Lixin Zhang-Auberson,[...]. N Engl J Med 2010
12


A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Gavin Giovannoni, Giancarlo Comi, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Peter Chang, Anthony Hamlett, Bruno Musch,[...]. N Engl J Med 2010
552
12

Reassessing B cell contributions in multiple sclerosis.
Rui Li, Kristina R Patterson, Amit Bar-Or. Nat Immunol 2018
189
12

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.
Martin Duddy, Masaaki Niino, Femina Adatia, Sherry Hebert, Mark Freedman, Harry Atkins, Ho Jin Kim, Amit Bar-Or. J Immunol 2007
457
12

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells.
Tom A Barr, Ping Shen, Sheila Brown, Vicky Lampropoulou, Toralf Roch, Sarah Lawrie, Boli Fan, Richard A O'Connor, Stephen M Anderton, Amit Bar-Or,[...]. J Exp Med 2012
411
12

Multiple Sclerosis.
Daniel S Reich, Claudia F Lucchinetti, Peter A Calabresi. N Engl J Med 2018
12

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson,[...]. Ann Neurol 2020
49
22

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Ralf Gold, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Gavin Giovannoni, Krzysztof Selmaj, Carlo Tornatore, Marianne T Sweetser, Minhua Yang, Sarah I Sheikh,[...]. N Engl J Med 2012
11

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.
David Baker, Monica Marta, Gareth Pryce, Gavin Giovannoni, Klaus Schmierer. EBioMedicine 2017
161
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.